|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Nun-Anan P and Vilaichone RK: Late stage
and grave prognosis of esophageal cancer in Thailand. Asian Pac J
Cancer Prev. 16:1747–1749. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Morita M, Kumashiro R, Kubo N, Nakashima
Y, Yoshida R, Yoshinaga K, Saeki H, Emi Y, Kakeji Y, Sakaguchi Y,
et al: Alcohol drinking, cigarette smoking, and the development of
squamous cell carcinoma of the esophagus: Epidemiology, clinical
findings, and prevention. Int J Clin Oncol. 15:126–134.
2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Toh Y, Oki E, Ohgaki K, Sakamoto Y, Ito S,
Egashira A, Saeki H, Kakeji Y, Morita M, Sakaguchi Y, et al:
Alcohol drinking, cigarette smoking, and the development of
squamous cell carcinoma of the esophagus: Molecular mechanisms of
carcinogenesis. Int J Clin Oncol. 15:135–144. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Huang FL and Yu SJ: Esophageal cancer:
Risk factors, genetic association, and treatment. Asian J Surg.
41:210–215. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hsu PK, Chen HS, Huang CS, Liu CC, Hsieh
CC, Hsu HS, Wu YC and Wu SC: Patterns of recurrence after
oesophagectomy and postoperative chemoradiotherapy versus surgery
alone for oesophageal squamous cell carcinoma. Br J Surg.
104:90–97. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pasquali S, Yim G, Vohra RS, Mocellin S,
Nyanhongo D, Marriott P, Geh JI and Griffiths EA: Survival after
neoadjuvant and adjuvant treatments compared to surgery alone for
resectable esophageal carcinoma: A network meta-analysis. Ann Surg.
265:481–491. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ando N, Iizuka T, Ide H, Ishida K, Shinoda
M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, et al:
Surgery plus chemotherapy compared with surgery alone for localized
squamous cell carcinoma of the thoracic esophagus: A Japan clinical
oncology group study-JCOG9204. J Clin Oncol. 21:4592–4596.
2003.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ando N, Kato H, Igaki H, Shinoda M, Ozawa
S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, et al: A
randomized trial comparing postoperative adjuvant chemotherapy with
cisplatin and 5-fluorouracil versus preoperative chemotherapy for
localized advanced squamous cell carcinoma of the thoracic
esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Haisley KR, Hart KD, Nabavizadeh N, Bensch
KG, Vaccaro GM, Thomas CR Jr, Schipper PH, Hunter JG and Dolan JP:
Neoadjuvant chemoradiotherapy with concurrent
cisplatin/5-fluorouracil is associated with increased pathologic
complete response and improved survival compared to
carboplatin/paclitaxel in patients with locally advanced esophageal
cancer. Dis Esophagus. 30:1–7. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Rumiato E, Cavallin F, Boldrin E, Cagol M,
Alfieri R, Basso D, Castoro C, Ancona E, Amadori A, Ruol A and
Saggioro D: ERCC1 C8092A (rs3212986) polymorphism as a predictive
marker in esophageal cancer patients treated with
cisplatin/5-FU-based neoadjuvant therapy. Pharmacogenet Genomics.
23:597–604. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Miyata H, Yoshioka A, Yamasaki M,
Nushijima Y, Takiguchi S, Fujiwara Y, Nishida T, Mano M, Mori M and
Doki Y: Tumor budding in tumor invasive front predicts prognosis
and survival of patients with esophageal squamous cell carcinomas
receiving neoadjuvant chemotherapy. Cancer. 115:3324–3334.
2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297.
2004.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chakraborty C, Chin KY and Das S:
miRNA-regulated cancer stem cells: Understanding the property and
the role of miRNA in carcinogenesis. Tumour Biol. 37:13039–13048.
2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Barbato S, Solaini G and Fabbri M:
MicroRNAs in oncogenesis and tumor suppression. Int Rev Cell Mol
Biol. 333:229–268. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Svoronos AA, Engelman DM and Slack FJ:
OncomiR or tumor suppressor? The duplicity of microRNAs in cancer.
Cancer Res. 76:3666–3670. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hemmatzadeh M, Mohammadi H, Karimi M,
Musavishenas MH and Baradaran B: Differential role of microRNAs in
the pathogenesis and treatment of esophageal cancer. Biomed
Pharmacother. 82:509–519. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sakai NS, Samia-Aly E, Barbera M and
Fitzgerald RC: A review of the current understanding and clinical
utility of miRNAs in esophageal cancer. Semin Cancer Biol.
23:512–521. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hummel R, Sie C, Watson DI, Wang T, Ansar
A, Michael MZ, Van der Hoek M, Haier J and Hussey DJ: MicroRNA
signatures in chemotherapy resistant esophageal cancer cell lines.
World J Gastroenterol. 20:14904–14912. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Slotta-Huspenina J, Drecoll E, Feith M,
Habermehl D, Combs S, Weichert W, Bettstetter M, Becker K and
Langer R: MicroRNA expression profiling for the prediction of
resistance to neoadjuvant radiochemotherapy in squamous cell
carcinoma of the esophagus. J Transl Med. 16(109)2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Betel D, Wilson M, Gabow A, Marks DS and
Sander C: The microRNA.org resource: Targets and expression.
Nucleic Acids Res. 36 (Database issue):D149–D153. 2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Vellayappan BA, Soon YY, Ku GY, Leong CN,
Lu JJ and Tey JC: Chemoradiotherapy versus chemoradiotherapy plus
surgery for esophageal cancer. Cochrane Database Syst Rev.
8(CD010511)2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kidane B, Coughlin S, Vogt K and Malthaner
R: Preoperative chemotherapy for resectable thoracic esophageal
cancer. Cochrane Database Syst Rev. (CD001556)2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hao X, Xia L, Qu R, Yang X, Jiang M and
Zhou B: Association between miR-146a rs2910164 polymorphism and
specific cancer susceptibility: An updated meta-analysis. Fam
Cancer. 17:459–468. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Shi L, Xu Z, Wu G, Chen X, Huang Y, Wang
Y, Jiang W and Ke B: Up-regulation of miR-146a increases the
sensitivity of non-small cell lung cancer to DDP by downregulating
cyclin J. BMC Cancer. 17(138)2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Tan W, Liao Y, Qiu Y, Liu H, Tan D, Wu T,
Tang M, Zhang S and Wang H: miRNA 146a promotes chemotherapy
resistance in lung cancer cells by targeting DNA damage inducible
transcript 3 (CHOP). Cancer Lett. 428:55–68. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Liao YQ, Liao YL, Li J, Peng LX, Wan YY
and Zhong R: Polymorphism in miR-146a associated with clinical
characteristics and outcomes in gastric cancer patients treated
with adjuvant oxaliplatin and fluoropyrimidines. Onco Targets Ther.
8:2627–2633. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Xue L, Nan J, Dong L, Zhang C, Li H, Na R,
He H and Wang Y: Upregulated miR-483-5p expression as a prognostic
biomarker for esophageal squamous cell carcinoma. Cancer Biomark.
19:193–197. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Fan S, Chen WX, Lv XB, Tang QL, Sun LJ,
Liu BD, Zhong JL, Lin ZY, Wang YY, Li QX, et al: miR-483-5p
determines mitochondrial fission and cisplatin sensitivity in
tongue squamous cell carcinoma by targeting FIS1. Cancer Lett.
362:183–191. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Cui XB, Peng H, Li RR, Mu JQ, Yang L, Li
N, Liu CX, Hu JM, Li SG, Wei Y, et al: MicroRNA-34a functions as a
tumor suppressor by directly targeting oncogenic PLCE1 in Kazakh
esophageal squamous cell carcinoma. Oncotarget. 8:92454–92469.
2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Song C, Lu P, Sun G, Yang L and Wang Z and
Wang Z: miR-34a sensitizes lung cancer cells to cisplatin via
p53/miR-34a/MYCN axis. Biochem Biophys Res Commun. 482:22–27.
2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sun C, Wang FJ, Zhang HG, Xu XZ, Jia RC,
Yao L and Qiao PF: miR-34a mediates oxaliplatin resistance of
colorectal cancer cells by inhibiting macroautophagy via
transforming growth factor-β/Smad4 pathway. World J Gastroenterol.
23:1816–1827. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhang Q, Wang J, Li N, Liu Z, Chen Z, Li
Z, Lai Y, Shen L and Gao J: miR-34a increases the sensitivity of
colorectal cancer cells to 5-fluorouracil in vitro and in vivo. Am
J Cancer Res. 8:280–290. 2018.PubMed/NCBI
|
|
35
|
Xue L, Yu X, Jiang X, Deng X, Mao L, Guo
L, Fan J, Fan Q, Wang L and Lu SH: TM4SF1 promotes the self-renewal
of esophageal cancer stem-like cells and is regulated by miR-141.
Oncotarget. 8:19274–19284. 2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wang F, Zhao L, Zhang J, Meng Z, Zhou C
and Wang G, Liu Y, Li M, Xi J, Niu W and Wang G:
Chemotherapy-induced miR-141/MAP4K4 signaling suppresses
progression of colorectal cancer. Biosci Rep.
38(BSR20180978)2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Li S, Zhu J, Li J, Li S and Li B:
MicroRNA-141 inhibits proliferation of gastric cardia
adenocarcinoma by targeting MACC1. Arch Med Sci. 14:588–596.
2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Fang S, Zeng X, Zhu W, Tang R, Chao Y and
Guo L: Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by
miR-200b contributes to multi-drug resistance of small cell lung
cancer. Exp Mol Pathol. 96:438–444. 2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Yu H, Duan B, Jiang L, Lin M, Sheng H,
Huang J and Gao H: Serum miR-200c and clinical outcome of patients
with advanced esophageal squamous cancer receiving platinum-based
chemotherapy. Am J Transl Res. 6:71–77. 2013.PubMed/NCBI
|
|
40
|
Heydari K, Saidijam M, Sharifi MR, Dermani
FK, Soleimani Asl S, Shabab N and Najafi R: The effect of miR-200c
inhibition on chemosensitivity (5-FluoroUracil) in colorectal
cancer. Pathol Oncol Res. 24:145–151. 2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Hur K, Toiyama Y, Takahashi M, Balaguer F,
Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR and Goel A:
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT)
in human colorectal cancer metastasis. Gut. 62:1315–1326.
2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Diaz T, Tejero R, Moreno I, Ferrer G,
Cordeiro A, Artells R, Navarro A, Hernandez R, Tapia G and Monzo M:
Role of miR-200 family members in survival of colorectal cancer
patients treated with fluoropyrimidines. J Surg Oncol. 109:676–683.
2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Hezova R, Kovarikova A, Srovnal J,
Zemanova M, Harustiak T, Ehrmann J, Hajduch M, Sachlova M, Svoboda
M and Slaby O: MiR-205 functions as a tumor suppressor in
adenocarcinoma and an oncogene in squamous cell carcinoma of
esophagus. Tumour Biol. 37:8007–8018. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Pan F, Mao H, Bu F, Tong X, Li J, Zhang S,
Liu X, Wang L, Wu L, Chen R, et al: Sp1-mediated transcriptional
activation of miR-205 promotes radioresistance in esophageal
squamous cell carcinoma. Oncotarget. 8:5735–5752. 2017.PubMed/NCBI View Article : Google Scholar
|
